First Reliance Bancshares Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of First Reliance Bancshares, Inc.

A law firm-led investigation is underway into the proposed sale of First Reliance Bancshares (OTC: FSRL) to Colony Bankcorp (NYSE: CBAN). Under the deal, First Reliance shareholders would receive $19.75 in cash or 0.94 shares of Colony common stock for each share held. The announcement adds deal-uncertainty that could weigh on investor confidence until the review concludes.

Analysis

This reads more like a deal-quality and process risk event than a fundamental impairment. The immediate pressure is on FSRL’s spread: once a litigation adviser enters, arbitrage desks typically widen required carry because the downside becomes delay, renegotiation, or a modest bump in consideration rather than outright failure. CBAN’s real exposure is not the headline itself, but whether the transaction forces equity issuance at a time when regional-bank valuations remain balance-sheet sensitive; if the stock leg is used heavily, dilution and multiple compression can offset any strategic benefit.

Second-order, the bigger signal is to the regional-bank M&A market. If this deal attracts real scrutiny, smaller banks with mixed cash/stock structures may see higher implied closing risk and wider spreads, especially names trading near tangible book with limited upside to compensate for process risk. That said, these investigations are often noise unless they uncover process defects, conflicted board behavior, or a weak fairness opinion; absent that, the odds favor eventual close with a narrower premium than initially implied, not a broken deal.

The contrarian view is that the market may be overpricing the legal headline because the company has already chosen a familiar, consolidating-bank buyer and the consideration includes a cash floor. In that setup, the real thesis question is not litigation, but whether the premium is large enough relative to standalone bank earnings power. If the spread implies a low annualized return after fees and time, this is closer to a wait-for-filing event than an actionable arb long.

Catalyst path: next 2-6 weeks for definitive proxy / supplemental disclosures; 1-3 months for any amended terms or shareholder vote positioning; 6-18 months for broader regional-bank deal-compression if legal scrutiny becomes a recurring issue. Falsifier: a tightened spread after filing support, no adverse disclosure in the proxy, or a quick consent/settlement from the investigating firm.

Key Decisions for Investors

• Do not initiate a standalone directional position in CBAN on the headline alone; wait for the proxy/8-K to quantify cash-vs-stock mix and closing protections before sizing any event trade.
• If FSRL trades at a material discount to implied deal value after fees, consider a small merger-arb long FSRL / short CBAN hedge only if annualized spread compensates for legal delay risk; target a 2-6 week catalyst window.
• On any CBAN rally tied to perceived deal certainty, use it to short into strength if the stock consideration dominates the mix and the pro forma dilution looks modestly accretive at best; invalidation is a clean proxy filing with no disclosed issues.
• Use KRE as the clean sector hedge: if this spreads beyond one deal and regional-bank M&A names start underperforming, a short CBAN / long KRE relative-value pair can isolate transaction-specific risk over a 1-3 month horizon.
• Set an alert on the FSRL spread: if it narrows back toward implied value before disclosure, the litigation overhang is likely overstated; if it widens materially after proxy release, the market is pricing real process risk and a break/renegotiation trade becomes viable.